Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITANIA trial of tozorakimab in symptomatic COPD with prior exacerbations
2021-003771-34Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tozorakimab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers. Started Oct 2021; status: active.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2021-003771-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003771-34.